Nexalin Technology Announces Clinical Study Data In Major Depressive Disorder And Publication Of Clinical Trial Results In Leading Scientific Journal 'Brain Stimulation'

6/26/24 9:01:28 AM ET

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Get the next $NXL alert in real time by email

Study demonstrates strong statistical separation between patients receiving Nexalin's DIFS® technology in combination with escitalopram (Lexapro) vs sham group receiving escitalopram alone

Two-thirds of patients receiving the combination therapy showed improvement

compared to just one-third of patients receiving medication alone

HOUSTON, June 26, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW))) (the "Company" or "Nexalin") today announced positive results of a clinical study designed to evaluate the feasibility, safety, and efficacy of transcranial alternating current dynamic frequency stimulation (tACS) as an add-on treatment for the symptoms of major depressive disorder (MDD), also known as clinical depression, a mental health condition that affects mood, behavior, appetite, and sleep.

Get the next $NXL alert in real time by email

Nexalin Technology Announces Clinical Study Data In Major Depressive Disorder And Publication Of Clinical Trial Results In Leading Scientific Journal 'Brain Stimulation'

Chat with this insight

Recent Analyst Ratings for
$NXL

$NXL
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Owens David bought $1,095 worth of shares (500 units at $2.19), increasing direct ownership by 0.34% to 148,293 units (SEC Form 4)

Chief Medical Officer Owens David bought $950 worth of shares (1,000 units at $0.95), increasing direct ownership by 0.68% to 147,793 units (SEC Form 4)

Chief Medical Officer Owens David bought $1,750 worth of shares (1,000 units at $1.75), increasing direct ownership by 0.69% to 146,793 units (SEC Form 4)

$NXL
Market Insights

Live Market Insights

EXCLUSIVE: Top 10 Most Searched Tickers On Benzinga Pro In June — Where Do Nvidia, GameStop, Tesla, Apple Rank?

Nexalin Technology shares are trading lower after the company announced the pricing of a $5.25 million public offering of 3 million shares at $1.75 per share.

Reported Earlier, Nexalin Technology Raises $5.25M Via Public Offering Of 3M Shares At $1.75/Share

$NXL
Leadership Updates

Live Leadership Updates

$NXL
Press Releases

Fastest customizable press release news feed in the world

Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

Nexalin Technology CEO Provides Letter to Shareholders

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

$NXL
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Owens David bought $1,095 worth of shares (500 units at $2.19), increasing direct ownership by 0.34% to 148,293 units (SEC Form 4)

Amendment: Large owner Elson Marilyn was granted 700,000 shares, increasing direct ownership by 84% to 1,535,244 units (SEC Form 4)

Director Bernhard Leslie was granted 49,838 shares (SEC Form 4)

$NXL
SEC Filings

SEC Form 10-Q filed by Nexalin Technology Inc.

Nexalin Technology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Nexalin Technology Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

$NXL
Financials

Live finance-specific insights

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin Technology Announces Clinical Study Data In Major Depressive Disorder And Publication Of Clinical Trial Results In Leading Scientific Journal 'Brain Stimulation'

Chat with this insight

Recent Analyst Ratings for $NXL

$NXL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Owens David bought $1,095 worth of shares (500 units at $2.19), increasing direct ownership by 0.34% to 148,293 units (SEC Form 4)

Chief Medical Officer Owens David bought $950 worth of shares (1,000 units at $0.95), increasing direct ownership by 0.68% to 147,793 units (SEC Form 4)

Chief Medical Officer Owens David bought $1,750 worth of shares (1,000 units at $1.75), increasing direct ownership by 0.69% to 146,793 units (SEC Form 4)

$NXL Market Insights

Live Market Insights

EXCLUSIVE: Top 10 Most Searched Tickers On Benzinga Pro In June — Where Do Nvidia, GameStop, Tesla, Apple Rank?

Nexalin Technology shares are trading lower after the company announced the pricing of a $5.25 million public offering of 3 million shares at $1.75 per share.

Reported Earlier, Nexalin Technology Raises $5.25M Via Public Offering Of 3M Shares At $1.75/Share

$NXL Leadership Updates

Live Leadership Updates

$NXL Press Releases

Fastest customizable press release news feed in the world

Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

Nexalin Technology CEO Provides Letter to Shareholders

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

$NXL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Owens David bought $1,095 worth of shares (500 units at $2.19), increasing direct ownership by 0.34% to 148,293 units (SEC Form 4)

Amendment: Large owner Elson Marilyn was granted 700,000 shares, increasing direct ownership by 84% to 1,535,244 units (SEC Form 4)

Director Bernhard Leslie was granted 49,838 shares (SEC Form 4)

$NXL SEC Filings

SEC Form 10-Q filed by Nexalin Technology Inc.

Nexalin Technology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Nexalin Technology Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

$NXL Financials

Live finance-specific insights

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Recent Analyst Ratings for
$NXL

$NXL
Insider Purchases

$NXL
Market Insights

$NXL
Leadership Updates

$NXL
Press Releases

$NXL
Insider Trading

$NXL
SEC Filings

$NXL
Financials